028) (Online resource 2). Significant subject characteristics after crossover were BMQ scores for necessity (p = 0.006), concern (p = 0.025), and preference (p = 0.024). Exploratory endpoints: bone mineral density and bone turnover markers Mean percentage MK-0457 datasheet changes in BMD (observed data) in the first year for the alendronate and denosumab groups, respectively,

were as follows: lumbar spine, 4.9% (n = 93) and 5.6% (n = 93); total hip, 2.5% (n = 102) and 3.2% (n = 109); and femoral neck, 2.0% (n = 102) and 3.1% (n = 109). Mean percentage BMD changes from baseline of the second year to the end of treatment for alendronate and denosumab, respectively, were as follows: lumbar spine, 0.6% (n = 82) and 2.9% (n = 92); total hip, 0.4% (n = 92) and 1.5% (n = 102); and femoral neck, −0.1% (n = 92) and 1.7% (n = 102). Median CTX-1 levels at baseline, the end of the first year, and the GSK1120212 molecular weight end of treatment, respectively, were as follows: denosumab/alendronate sequence, 0.465 ng/mL (n = 75), 0.139 ng/mL (n = 108), and 0.223 ng/mL (n = 92); alendronate/denosumab sequence, 0.435 ng/mL (n = 81), 0.132 ng/mL (n = 100), BVD-523 mw and 0.140 ng/mL (n = 100). Median values for P1NP levels at baseline, the end of the first year, and the end of treatment, respectively, were as follows: denosumab/alendronate

sequence, 50.06 μg/L (n = 75), 14.97 μg/L (n = 108), and 21.73 μg/L (n = 92); alendronate/denosumab sequence, 53.37 μg/L (n = 81), 17.26 μg/L (n = 100), and 16.96 μg/L (n = 100). At baseline, no subject in either treatment group had a CTX-1 level below the limit of quantification. At the end of the first year, 2/108 (1.9%) subjects in the denosumab group and 3/100

(3.0%) subjects in the alendronate group had undetectable CTX-1 levels. Six months after crossover, 13/86 (15.1%) subjects in the denosumab group and 4/97 (4.1%) subjects in the alendronate group had undetectable CTX-1 levels. At the end of study, 15/100 (15.0%) subjects in the denosumab group and 6/92 (6.5%) subjects in the alendronate group had undetectable CTX-1 levels. Safety The safety population included 228 subjects who received at least one dose of alendronate and 230 subjects who received at least one dose of denosumab. Adverse events with incidence Florfenicol rates >2% by preferred term in either treatment group were not significantly different between treatment groups in the second treatment period. Overall, 63.2% and 65.7% of subjects reported at least one adverse event during alendronate and denosumab treatment, respectively. Adverse events reported by at least 5% of subjects during either treatment (alendronate, denosumab) were arthralgia (6.6%, 6.1%), pain in extremity (3.9%, 6.1%), and back pain (5.7%, 3.9%). Adverse events of fracture during the first year included one subject with fibula fracture during alendronate treatment and one with foot fracture during denosumab treatment.